Objective To assess the efficacy and safety of Bevacizumab combined with  Radiotherapy-Temozolomide to treat newly diagnosed glioblastoma. Methods PubMed， The Cochrane Library，EMBASE，and the Wanfang Database were systematically searched for relevant clinical studies. Two researchers assessed trial quality according to the Cochrane Manual and extracted data independently. Data were analyzed using RevMan 5.3. Result Four prospective clinical trials，including two randomized controlled trials，were included in the review；these trials involved 891 patients who received Bevacizumab combined with radiotherapy-temozolomide and 882 control patients who received radiotherapy-temozolomide. Meta-analysis indicated that combination therapy was associated with significantly higher 6-month progression-free survival（PFS；RR 0.44，95%CI 0.37-0.52，P＜0.001），12-month PFS（RR 0.78，95%CI  0.73-0.84，P＜0.001）and 12-month overall survival（RR 0.86，95%CI  0.74-0.99，P=0.03）. At the same time， combination therapy was associated with significantly higher incidence of hypertension（RR 3.11，95%CI  2.39-4.06，P＜0.001） and bleeding （RR 1.85，95%CI  1.50-2.27，P＜0.001）. Incidence of vascular thrombus diseases，wound-healing complications and internal organ perforation was similar for the two therapies. All treatment-related adverse events were easily resolved. Conclusions Bevacizumab combined with radiotherapy-temozolomide can prolong progression-free and overall survival in patients with newly diagnosed glioblastoma， but it increases the risk of some adverse reactions.